Medtronic to acquire Contego Medical for $380 million
Medtronic (NYSE:MDT) plans to acquire Contego Medical, a private medical device firm, for $380 million, with potential additional payments. The deal, expected to close in Q3 FY2025, expands Medtronic's carotid and peripheral vascular treatments. Contego's Neuroguard and Excipio devices will join Medtronic's portfolio. The acquisition is expected to be minimally dilutive to earnings in FY2027-2028, then neutral to accretive.
How this was made
The 30-second read
Why it matters
The acquisition adds FDA‑cleared carotid and thrombectomy technologies, aligning with Medtronic's growth strategy.
Market read
A material M&A announcement for a large‑cap healthcare company, likely to influence its stock and sector peers.
What to watch
Potential regulatory review timelines and the actual cash availability for the transaction.
Background
Medtronic (NYSE:MDT) is a leading global medical technology company expanding its vascular treatment portfolio.
Ticker impact
Medtronic announced a $380 million acquisition of private Contego Medical, expanding its carotid and peripheral vascular portfolio.
likely modest upside as investors price in the strategic expansion and accretive potential
Large‑cap M&A with clear financial impact and no immediate financing strain typically supports a bullish reaction.
Market effects
strengthens Medtronic's position in the vascular device market, potentially pressuring peers.
U.S. healthcare sector may see slight uplift from the strategic acquisition.
limited to medical device industry, no broad market effect.
Counterpoint
Deal could be seen as overpaying for a niche private firm, risking integration challenges.
Key entities
- companyMedtronic plc
US‑listed medical device manufacturer (NYSE:MDT).
- companyContego Medical
Privately held developer of carotid artery disease and peripheral thrombectomy solutions.


